大麻使用与心律失常的关联:一项系统综述
该系统综述检索了PubMed、Google Scholar和OpenGrey,按牛津循证医学中心指南对文献分级。共纳入1篇Ⅰ级系统综述与荟萃分析(含6项人体研究)、16项Ⅱ级研究(6942名受试者)、9项Ⅲ级研究(3797096名受试者)及2篇系统与范围综述(30例病例)。Ⅰ-Ⅲ级文章中61%强调大麻诱导的心动过速,29%描述心律失常;Ⅳ-Ⅴ级文章共42例,平均年龄30±12岁,24%为女性,最常见心律失常为心室颤动(21%),其次为心房颤动(19%)、室性心动过速(12%)、三度房室传导阻滞(12%)和无收缩(12%),8例心脏骤停中5例死亡。结论认为大麻使用与心律失常风险增加相关,临床医生和护士应询问患者的大麻使用情况并对患者进行教育。
要点
- 大麻使用与心律失常风险增加相关,虽少见但可能危及生命。
- Ⅰ-Ⅲ级文章中61%(17/28)强调大麻诱导的心动过速,29%(8/28)描述心律失常。
- Ⅰ-Ⅲ级文章报告的具体心律失常包括心房颤动、心房扑动、房室传导阻滞、室性期前收缩、房性期前收缩、室性心动过速和心室颤动。
- Ⅳ-Ⅴ级文章42例中,最常见心律失常为心室颤动(21%),其次为心房颤动(19%)、室性心动过速(12%)、三度房室传导阻滞(12%)和无收缩(12%)。
- Ⅳ-Ⅴ级文章中有8例心脏骤停,其中5例死亡;仅1项Ⅲ级研究报告大麻使用与心力衰竭住院患者心房颤动风险降低相关(比值比=0.87)。
适用人群与场景
- 表现为心动过速、心动过缓、心律失常、胸痛和/或不明原因晕厥的患者,应询问急性与慢性大麻使用情况。
- 使用大麻的患者,尤其是那些有基础心脏病或危险因素者,应接受关于此有害关联的教育。
红旗征与不能漏的情况
- 心室颤动、室性心动过速、三度房室传导阻滞、无收缩和心脏骤停等可能危及生命的心律失常。
- Ⅳ-Ⅴ级文章中报告8例心脏骤停,其中5例死亡。
- 心电图上ST段抬高(29%)、V1、V2导联Brugada波型(14%)和右束支传导阻滞(12%)。
研究设计与关键结果
- 系统综述纳入1篇Ⅰ级系统综述与荟萃分析(含6项人体研究)、16项Ⅱ级研究(6942名受试者)、9项Ⅲ级研究(3797096名受试者)和2篇系统与范围综述(30例病例)。
- Ⅰ-Ⅲ级文章中,61%(17/28)强调大麻诱导的心动过速,29%(8/28)描述心律失常。
- Ⅰ-Ⅲ级文章报告的具体心律失常包括心房颤动、心房扑动、房室传导阻滞、室性期前收缩、房性期前收缩、室性心动过速和心室颤动,其他心电图表现包括ST段抬高、P波和T波改变。
- 仅1项Ⅲ级研究报告大麻使用与心力衰竭住院患者心房颤动风险降低相关(比值比=0.87)。
- Ⅳ-Ⅴ级文章共42例,平均年龄30±12岁,24%(10例)为女性;最常见心律失常为心室颤动(21%),其次为心房颤动(19%)、室性心动过速(12%)、三度房室传导阻滞(12%)和无收缩(12%),症状性心动过缓4例(10%)。
- Ⅳ-Ⅴ级文章中心电图改变包括ST段抬高(29%)、V1、V2导联Brugada波型(14%)和右束支传导阻滞(12%);心脏骤停8例,其中5例死亡。
证据类型、等级与局限
- 证据类型:系统综述,按牛津循证医学中心指南对临床研究、观察性研究、回顾性研究、病例系列和病例报告进行分级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 临床医生和护士应询问表现为心动过速、心动过缓、心律失常、胸痛和/或不明原因晕厥患者的急性与慢性大麻使用情况。
- 使用大麻的患者应接受关于此有害关联的教育,尤其是那些有基础心脏病或危险因素者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Cannabis use results in elevation of heart rate and blood pressure immediately after use, primarily due to sympathetic nervous system stimulation and parasympathetic nervous system inhibition. These effects may precipitate cardiac dysrhythmia. The objective of our study was to analyze systematically the pertinent medical literature regarding the putative association between cannabis use and cardiac dysrhythmia.Methods: We queried PubMed, Google Scholar, and OpenGrey, and reviewed results for relevance. We graded clinical trials, observational and retrospective studies, case series and reports using Oxford Centre for Evidence-Based Medicine guidelines.Results: The relevant publications identified included one Level I systematic review and meta-analysis of six human studies, 16 Level II studies with 6,942 subjects, nine Level III studies with 3,797,096 subjects and two systematic and scoping reviews with 30 cases. Cannabis-induced tachycardia was highlighted in 17 of 28 (61%) Level I-III articles followed by a generalized description of dysrhythmia in eight (29%). Specific dysrhythmias noted in the Level I-III articles included atrial fibrillation, atrial flutter, atrioventricular block, premature ventricular contractions, premature atrial contractions, ventricular tachycardia, and ventricular fibrillation. Other reported findings on electrocardiogram included ST segment elevation, P, and T wave changes. Only one Level III study reported a decreased risk of atrial fibrillation from cannabis use in patients hospitalized for heart failure (Odds ratio = 0.87). There were 39 case series (Level IV) and case reports (Level V) with 42 subjects. Average age was 30 ± 12 years, and only ten (24%) were female. The most common dysrhythmia mentioned in the Level IV and V articles was ventricular fibrillation (21%), followed by atrial fibrillation (19%), ventricular tachycardia (12%), third degree atrioventricular block (12%), and asystole (12%). There were four cases (10%) of symptomatic bradycardia. Notable electrocardiographic changes included ST segment elevation (29%), Brugada pattern in leads V1, V2 (14%), and right bundle branch block (12%). There were eight cases of cardiac arrest, of whom five expired.Conclusion: Cannabis use is associated with increased risk of cardiac dysrhythmia, which is rare but may be life-threatening. Clinicians and nurses should inquire about acute and chronic cannabis use in their patients presenting with tachycardia, bradycardia, dysrhythmia, chest pain, and/or unexplained syncope. Patients who use cannabis should be educated on this deleterious association, especially those with underlying cardiac disease or risk factors.
参考来源
- Richards JR, Blohm E, Toles KA, et al. The association of cannabis use and cardiac dysrhythmias: a systematic review. Clin Toxicol (Phila). 2020. PMID: 32267189. doi:10.1080/15563650.2020.1743847
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。